EQS-News: RHÖN-KLINIKUM Aktiengesellschaft
/ Key word(s): Half Year Results/Miscellaneous
Corporate News Bad Neustadt a. d. Saale | 8 August 2024 First half of 2024: RHÖN-KLINIKUM AG continues good business performance – RHÖN-KLINIKUM AG closed the first half of 2024 with a 6.5% increase in revenues to 775.5 million euros (H1 2023: 728.2 million euros). Despite a challenging market environment, consolidated profit increased by 68.9% to reach EUR 20.6 million (H1 2023: EUR 12.2 million). From January to June 2024 a total of 463,111 patients were treated on an inpatient and outpatient basis in the Group’s hospitals and medical care centres, 3.8% more compared with the same period of the previous year (H1 2023: 446,022). At 49.1 million euros, EBITDA was above the previous year’s level (H1 2023: 45.2 million euros). Materials and consumables used increased as a result of higher purchasing prices and the provision of material cost-intensive services to 266.2 million euros (H1 2023: 237.0 million euros). “RHÖN-KLINIKUM AG is a sound, efficient and economically responsible company. Our five hospital sites
For the current financial year, RHÖN-KLINIKUM AG continues to expect revenues of 1.6 billion euros within The outlook is subject to considerable uncertainties in connection with the numerous global crises in the form of inflation and price increases and any regulatory measures impacting our remuneration structure The 2024 Half-Year Report is published on the Internet. RHÖN-KLINIKUM AG is one of the largest healthcare providers in Germany. The hospitals offer excellent medical care with a direct tie-in to universities and research facilities. Each year some 882,000 patients are treated at our five sites – RHÖN-KLINIKUM Campus Bad Neustadt, Klinikum Frankfurt (Oder), Universitätsklinikum Gießen and Universitätsklinikum Marburg (UKGM) as well as Zentralklinik Bad Berka. The Company employs over 18,200 persons. The innovative RHÖN Campus approach committed to cross-sector and future-oriented healthcare delivery in rural areas, the steadfast continuation of the gradual digital transformation within the Company as well as the strategic partnership with Asklepios are key elements of our corporate strategy. RHÖN-KLINIKUM AG is an independent Company operating under the umbrella of Asklepios Kliniken GmbH & Co. KGaA. www.rhoen-klinikum-ag.com Contact: RHÖN-KLINIKUM AG | Head of Corporate Finance, Treasury, Investor Relations and Sustainability
08.08.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
Language: | English |
Company: | RHÖN-KLINIKUM Aktiengesellschaft |
Salzburger Leite 1 | |
97616 Bad Neustadt a. d. Saale | |
Germany | |
Phone: | +49 (0)9771 - 65-0 |
Fax: | +49 (0)9771 - 97 467 |
E-mail: | rka@rhoen-klinikum-ag.com |
Internet: | www.rhoen-klinikum-ag.com |
ISIN: | DE0007042301 |
WKN: | 704230 |
Listed: | Regulated Market in Frankfurt (Prime Standard), Munich; Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Stuttgart, Tradegate Exchange |
EQS News ID: | 1963561 |
End of News | EQS News Service |
|
1963561 08.08.2024 CET/CEST
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.